World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
60880
World Ranking
8406
National Ranking
4346

Ileana L. Pina publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ileana L. Pina sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 455 publications — 50th percentile

50% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ileana L. Pina D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ileana L. Pina sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ileana L. Pina is affiliated with Jefferson Healthcare in the United States and has a research focus predominantly in the field of Medicine, with a particular emphasis on Cardiology and Cardiovascular Medicine. Their work spans several subfields including Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine, Surgery, and Economics and Econometrics.

The scientist's research is concentrated around topics related to heart failure, cardiovascular function, and diabetes management. Major areas of study include:

  • Heart Failure Treatment and Management
  • Cardiovascular Function and Risk Factors
  • Cardiac pacing and defibrillation studies
  • Diabetes Treatment and Management
  • Potassium and Related Disorders
  • Cardiovascular and exercise physiology
  • Medication Adherence and Compliance

Ileana L. Pina has contributed to multiple publications, prominently in journals such as the Journal of Cardiac Failure, Journal of the American College of Cardiology, JACC Heart Failure, Circulation, and Circulation Heart Failure. The frequency of their publications in these venues includes:

  • Journal of Cardiac Failure: 23 publications
  • Journal of the American College of Cardiology: 21 publications
  • JACC Heart Failure: 15 publications
  • Circulation: 13 publications
  • Circulation Heart Failure: 11 publications

Some of the recent notable papers involving or related to their field are:

  • Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (2020, New England Journal of Medicine)
  • Empagliflozin in Heart Failure with a Preserved Ejection Fraction (2021, New England Journal of Medicine)
  • Cardiac Rehabilitation for Patients With Heart Failure (2021, Journal of the American College of Cardiology)
  • Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Scientific Statement From the American Heart Association (2021, Circulation)
  • Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial (2022, European Heart Journal)

Frequent co-authors in their research include:

  • Javed Butler
  • G. Michael Felker
  • James L. Januzzi
  • Scott D. Solomon
  • Mona Fiuzat

Best Publications

  • Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

    M. Packer;S. D. Anker;J. Butler;G. Filippatos

  • Exercise and Physical Activity in the Prevention and Treatment of Atherosclerotic Cardiovascular Disease A Statement From the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity)

    Paul D. Thompson;David Buchner;Ileana L. Piña;Gary J. Balady

  • Empagliflozin in heart failure with a preserved ejection fraction

    Stefan D Anker;Javed Butler;Gerasimos Filippatos;João P Ferreira

  • Forecasting the Impact of Heart Failure in the United States A Policy Statement From the American Heart Association

    Paul A. Heidenreich;Nancy M. Albert;Larry A. Allen;David A. Bluemke

  • Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.

    Christopher M. O'Connor;David J. Whellan;David J. Whellan;Kerry L. Lee;Steven J. Keteyian

  • Exercise Standards for Testing and Training A Scientific Statement From the American Heart Association

    Gerald F. Fletcher;Philip A. Ades;Paul Kligfield;Ross A. Arena

  • Statement on Exercise: Benefits and Recommendations for Physical Activity Programs for All Americans A Statement for Health Professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association

    Gerald F. Fletcher;Steven N. Blair;James Blumenthal;Carl Caspersen

  • Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness

    James A. Hill;Daniel F. Pauly;Debra R. Olitsky;Stuart Russell

  • Exercise and Heart Failure A Statement From the American Heart Association Committee on Exercise, Rehabilitation, and Prevention

    Ileana L. Piña;Carl S. Apstein;Gary J. Balady;Romualdo Belardinelli

  • Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.

    Michael S. Cuffe;Robert M. Califf;Kirkwood F. Adams;Raymond Benza

  • Guidelines for the Prevention of Stroke in Women A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

    Cheryl Bushnell;Louise D. McCullough;Issam A. Awad;Monique V. Chireau

  • Acute heart failure syndromes: current state and framework for future research.

    Mihai Gheorghiade;Faiez Zannad;George Sopko;Liviu Klein

  • Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update

    Lori Mosca;Emelia J. Benjamin;Kathy Berra;Judy L. Bezanson

  • Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial.

    Kathryn E. Flynn;Ileana L. Piña;David J. Whellan;David J. Whellan;Li Lin

  • Core Components of Cardiac Rehabilitation/Secondary Prevention Programs A Statement for Healthcare Professionals From the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation Writing Group

    Gary J. Balady;Philip A. Ades;Patricia Comoss;Marian Limacher

  • Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study.

    Liviu Klein;Christopher M. O'Connor;Jeffrey D. Leimberger;Wendy Gattis-Stough

  • Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.

    Laxmi S. Mehta;Karol E. Watson;Ana Barac;Theresa M. Beckie

  • ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society of America.

    Robert O. Bonow;Susan Bennett;Donald E. Casey;Theodore G. Ganiats

  • Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update

    Shannon M. Dunlay;Michael M. Givertz;David Aguilar;Larry A. Allen

  • Core Components of Cardiac Rehabilitation/Secondary Prevention Programs: Statement for Healthcare Professionals From the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation

    Gary J. Balady;Philip A. Ades;Terry Bazzarre;Patricia Comoss

Frequent Co-Authors

Robert J. Myerburg
Robert J. Myerburg University of Miami
Karl B. Kern
Karl B. Kern University of Arizona
Bruce Cohen
Bruce Cohen Northwestern University
Jonathan L. Halperin
Jonathan L. Halperin Icahn School of Medicine at Mount Sinai
Harold P. Adams
Harold P. Adams University of Iowa
Valentin Fuster
Valentin Fuster Icahn School of Medicine at Mount Sinai

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students exploring Medicine in the USA, there are several flexible online degree options and career pathways to consider. Many professionals start with rn to bsn programs, which help registered nurses expand their qualifications and career prospects. These programs are ideal for those seeking advancement without the need for on-site clinical hours.

Aspiring advanced practice nurses may opt for accelerated dnp programs to earn a Doctor of Nursing Practice in less time. Alternatively, some learners look for a dnp program without clinical hours, balancing work, study, and family commitments more effectively.

Those starting their careers can choose from the fastest lpn program options available online, which provide an entry point into nursing at a quicker pace. Each path offers unique benefits, allowing individuals to tailor their education to fit their schedule and career goals while meeting the demands of the evolving healthcare industry in the US.

Best Scientists Citing Ileana L. Pina

Trending Scientists

Recently Published Articles